铂生卓越生物科技

Beijing Bosen Zhuoyue Biotechnology is a clinical-stage biotechnology company headquartered in Beijing, China, specializing in the development of innovative cell therapies. The company focuses on chimeric antigen receptor T-cell (CAR-T) therapies, TCR-T, and stem cell-based treatments for oncology and regenerative medicine. Bosen Biotech maintains a robust research and development infrastructure, including GMP-compliant manufacturing facilities to support its clinical pipeline. Their lead programs target hematological malignancies such as B-cell lymphoma and multiple myeloma, with expanding efforts into solid tumor indications. By integrating advanced cell engineering with clinical translation, the company aims to deliver next-generation immunotherapies to patients with unmet medical needs. The firm also provides technical services and cell storage solutions as part of its broader healthcare ecosystem.